# EMBER-3 (NCT04975308)

> A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04975308
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Breast Neoplasms; Neoplasm Metastasis
- Interventions: Imlunestrant; Exemestane; Fulvestrant; Abemaciclib
- Enrollment: 874
- Primary outcome: Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)
- Primary outcome: Investigator-assessed PFS (Between Arm C and Arm A)
- Primary outcome: Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 138
- YouTube: 129
- Podcasts: 89
- Bluesky threads: 3
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ember-3-nct04975308

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04975308", "email": "<work email>"}; the inbox owner confirms by the emailed link.